



Renal Function after Nephron-Sparing Surgery vs. Radical Nephrectomy for Renal Cell Carcinoma: A Comparative Study

Ershad Hasan^{1*}, Shamim Hossain¹, Mohammad Abdus Salam^{1,2}, Muhammed Serajul Islam¹, Akterkamal Perveg¹ and A K Al-Miraj³

¹Department of Urology, BSMMU, Dhaka, Bangladesh

²Urology and Transplant Foundation of Bangladesh and Uro-Oncology, BSMMU, Dhaka, Bangladesh

³Department of Vascular Surgery, BSMMU, Dhaka, Bangladesh

Abstract

Background: Renal Cell Carcinoma (RCC) is the third most common malignancy of the genitourinary system characterized by lack of early warning clinical manifestations (asymptomatic) and late triad of symptoms (flank pain, hematuria, and palpable renal mass). It accounts for approximately 2% to 3% of the adult malignancy and 90% to 95% of neoplasm arising from the kidney. With the improvement in imaging technique, small and asymptomatic RCC is easily diagnosed and treated but advanced RCC is difficult to tract because its inherent resistance to conventional chemotherapy and radiotherapy. However, whether NSS is a better treatment than RN for RCCS still remains controversial. The recently published article reports that NSS substantially reduce the incidence of moderate renal dysfunction when compared with RN.

Objective: To compare the time-dependent changes of estimated Glomerular Filtration Rate (eGFR) after nephron-sparing surgery and Radical Nephrectomy (RN) for Renal Cell Carcinoma (RCC).

Type of study: Randomized controlled clinical trial.

Place of study: Department of Urology, BSMMU and others institutes-National Institute of Kidney Disease and Urology (NIKDU), Dhaka Medical College Hospital (DMCH), Comfort Nursing Home (Pvt.) Ltd. Dhaka, during the period of January, 2017 to September 2018.

Methods and Procedure: This prospective randomized controlled clinical trial study is conducted in the Department of Urology, BSMMU and other institutes-NIKDU, DMCH, Comfort Nursing Home (Pvt.) Ltd, Dhaka, from January, 2017 to September, 2018. Total 52 patients having renal cell carcinoma (<7 cm) and normal contralateral kidney, available preoperative and postoperative serum creatinine and MDRD-eGFR measurements are included in this study.

Results: Demographic characteristics, BMI, pre and post operative symptoms and sign of the patients, most of the tumor characteristics (location, hydronephrosis and enhancement) are not statistically significant in both groups but statistically significant changes are found in tumor size ($p=0.004$) and tumor type ($p=0.013$). There is no significant difference in preoperative serum creatinine and eGFR in both groups but the time-dependent changes of eGFR after RN show plateau form initially and then gradually declining form the first postoperative day to the 12 postoperative months. In case of NSS, a lowest eGFR is observing in postoperative day I and gradually recovered to near preoperative level for 12 months. The mean (+DD) eGFR decreased more significantly in RN (group-B 18.56 ml/min) than NSS patients (group-A 6.31 ml/min) from preoperative to 12 months after operation and show statistically significant differences between and within both groups ($p<0.001$, <0.001 respectively).

Conclusion: A Time dependent change of estimated Glomerular Filtration Rate (eGFR) after nephron-sparing surgery is better than Radical Nephrectomy (RN) for Renal Cell Carcinoma (RCC). NSS is therefore the better procedure for preservation of renal function.

Keywords: Demographic Characteristics; BMI; Radical Nephrectomy (RN); Renal Cell Carcinoma (RCC); Postoperative symptoms

OPEN ACCESS

*Correspondence:

Ershad Hasan, Department Of Urology,
BSMMU, Dhaka, Bangladesh,
E-mail: publication985@gmail.com

Received Date: 15 Mar 2021

Accepted Date: 15 Apr 2021

Published Date: 21 Apr 2021

Citation:

Hasan E, Hossain S, Abdus Salam M, Serajul Islam M, Perveg A, Al-Miraj AK. Renal Function after Nephron-Sparing Surgery vs. Radical Nephrectomy for Renal Cell Carcinoma: A Comparative Study. *Ann Urol Res.* 2021; 5(1): 1021.

Copyright © 2021 Ershad Hasan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Renal Cell Carcinoma (RCC) is the most common malignancy of the kidney and accounts for about 2% to 3% of all adult neoplasm's [1]. Overall, approximately 12 new cases are diagnosed per 100,000 population per year, with a male-to-female predominance of 3:2. This is primarily a disease of older adults, with typical presentation between 50 and 70 years of age [2]. The incidence of renal tumors has risen over the last decades. Due to the progress in radiological imaging, the majority of renal tumors are detected incidentally (<50%) during diagnostic work-up for other patient complaints. The triad of symptom-flank pain, gross hematuria, and palpable mass only occur in the minority of patients (7% to 10%) and are usually a sign of locally advanced disease [3]. Radical Nephrectomy (RN) has been the standard treatment for any Renal Cell Carcinoma (RCC) during the last 30 years. The role of open radical nephrectomy in the management of RCC has changed somewhat over the last decade [1]. Although Radical Nephrectomy (RN) has long been the standard treatment for Renal Cell Carcinoma (RCC), many studies have recently been documented the improved overall survival, better preservation of renal function, the safety and ontological efficacy of Nephron-Sparing Surgery (NSS) for RCC [3]. The current guidelines form the European Urology Association (EUA) and American Urology Association (AUA) have recommended NSS for RCCs smaller than 4 cm. Despite these recommendations, RN is still widely performed for small tumors in individuals with a normal contralateral kidney [4]. Nephron-Sparing Surgery (NSS) with resection of the tumor only was usually reserved for patients with solitary kidney, bilateral tumors or chronic kidney disease. It has become the standard of surgery for patients with solitary kidney, bilateral tumors or chronic kidney disease. It has become the standard of surgery for patients presenting with renal tumors <4 cm in size (cT1a) with a healthy contralateral kidney due to good ontological long-term outcomes with a moderate perioperative complication rate. In selected cases NSS is considered as alternative treatment for 4 cm to 7 cm sized renal tumors (cT1b). For renal tumors >7 cm in size (cT2a), NSS can also be performed safely in properly selected patients with good short-term functional and oncologic outcomes. Both RN and NSS are therefore considered standard treatments for RCC and the main difference in outcome between these procedures is the preservation of renal function [3]. Renal function after surgery for RCC has usually been assessed by using Serum Creatinine (SCr.0) level alone but SCr is affected by factors affecting generation, including muscle mass and dietary intake. As a result, renal function tends to be overestimate in patients who are elderly or for some other reason have decreased muscle mass. Furthermore, it is difficult to evaluate SCr level in both male and female patients because the normal ranges of serum creatinine differ between men and women. So eGFR is the most accurate index for assessing renal function and the National Kidney Foundation Kidney Disease Outcome Quality Initiative (NKF KEOQI) guidelines recommended using estimate glomerular with age, diabetes and hypertension [5]. In a study of 253 patients with RCC by Miyamoto et al. [6]. Have assessed the renal function using the eGRR and investigate the time dependent changes of the eGFR after the operation and found postoperative eGFR<60 ml/min is 23% and 57.6% in radial nephrectomy and nephron sparing surgery.

General objective

To compare renal functional status after nephron-sparing surgery and radical nephrectomy for renal cell carcinoma.

Specific objectives:

- To estimate serum creatinine among the patinas undergoing nephron-sparing surgery and radical nephrectomy before operation.
- To estimate serum creatinine among the patients undergoing nephron-sparing surgery and radical nephrectomy after operation at different interval.
- To estimate eGFR among the patents undergoing nephron-sparing surgery and radical nephrectomy before operation.
- To estimate eGFR among the patients undergoing nephron-sparing surgery and radical nephrectomy after operation at different interval.
- To compare eGFR among the patients undergoing nephron-sparing surgery and radical nephrectomy after operation at different interval.
- To compare eGFR between nephron-sparing surgery and radical nephrectomy patients.

Materials and Methods

Type of study: Randomized controlled clinical trail.

Study period: January 2017 to September 2018.

Study place: Department of Urology, Bangabandhu Sheikh Mujib Medical University and Toehr institutes in Dhaka-National Institute of Kidney Disease and Urology (NIKDU), Dhaka Medical Collage Hospital (DMCH) and Comfort Nursing Home (Pvt.) Ltd, Dhaka.

Study population

Patients having renal cell carcinoma (<7 cm) attending in the outpatient department of BSMMU hospital and other institutes in Dhaka- National Institute of Kidney Disease and Urology (NIKDU), Dhaka Medical College Hospital (MDCH) Comfort Nursing Home (Pvt.) Ltd, from January 2017 to September 2018 is included in this study and surgical intervention is done.

Inclusion criteria:

1. Age (35 to 75 years)
2. A solitary renal mass, size <7 cm (cT1a, Ctkb)
3. A radiographically normal contralateral Kidney.

Exclusion criteria:

1. Patient with a preoperative serum creatinine level >1.5 mg/dl
2. Patient with a preoperative glomerular filtration rate <30 ml/min/1.73 m²
3. Patient with a tumor in solitary kidney
4. Patient with bilateral or multiple renal tumors.
5. Contralateral unhealthy kidney.
6. Obese patients (BMI>30 Kg/M²)
7. Pregnant patient
8. Patient refusing consent
9. Patient missing or dead during follow up.

Sampling technique

Purposive sampling technique will be applied to collect the sample for this study who are admitted with the diagnosis of renal cell carcinoma in the department of urology, BSMMU and other mentioned institutes hospital in Dhaka are selected as per inclusion and exclusion criteria for the present study. After written informed consent, total 52 patients are recruited and divided into two groups by lottery method.

Study groups: There are two groups of study subjects.

Group-A: Patients who were undergone nephron sparing surgery by open method.

Group-B: Patients who were undergone radical nephrectomy by open method.

Preoperative variable:

1. BMI of the patient
2. Chronic disease/co-morbid disease-cardiovascular (HTN), DM.
3. Serum creatinine (mg/dl) eGFR (ml/min/1.93 m²)

Postoperative Variable (outcome Variable):

1. Serum creatinine (mg/dl)
2. eGFR (ml/min/1.73 m²)

Investigation

Diagnostic purpose:

1. USG of whole abdomen.
2. Computed tomography scan with urogram and angiogram.

Evaluation purpose:

1. Blood Hemoglobin level
2. Urine R/M/E and C/S
3. Serum electrolytes
4. RBS
5. CXR-P/A
6. Serum Creatinine
7. eGFR

Key steps of the procedure:

1. Patient was included in the study after fulfilling the selection criteria (inclusion and exclusion criteria).
2. Informed written consent was taken by all patients after explaining about the study, different management options, the possibility of response and the complications related to the procedure.
3. Preoperative general fitness of the patients was checked by physical examinations and investigations.
4. Under standard procedure, nephron sparing surgery in group-A patients and radical nephrectomy in group-B patients were performed.

Date collection

1. The study subjects were selected on the basis of inclusion

criteria from the patients who underwent nephron sparing surgery or radical nephrectomy in the Department of Urology, BSMMU and other institutes in Dhaka.

2. The demographic information, relevant medical history, examination findings and investigation reports of all the study subjects were recorded in the data collection sheet.

3. Any patient facing complications during the procedure was excluded from study.

4. Any patient facing complications during the procedure was excluded from study.

5. Any patient who died during follow up was excluded.

6. All patients were conducted over telephone as scheduled for follow up after initial treatment.

7. The data sheet was filled up after taking brief history, review of records and variable documents from patients.

Data analysis

1. After compilation, the data was presented in the form of tables, figures and graphs, as necessary.

2. Statistical analysis of the results was done by using computer based statistical software SPSS 20.0 version for windows operating system.

3. Results are expressed as mean \pm SD and compared by Student's unpaired (independent) and paired (dependent) t-test for continuous variables and Chi square test for categorical variables.

4. A 'p' value of <0.05 was considered as significant.

Renal cell carcinoma: Renal Cell Carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine (Figure 1).

Radical nephrectomy: The prototypical concept of RN encompasses the basic principles of early ligation of the renal artery and vein, removal of the kidney with primary dissection extremely to the Gerota fascia, excision of the ipsilateral adrenal gland, and performance of an extended lymphadenectomy from the crus of the diaphragm to the aortic bifurcation.

Nephron sparing surgery: An operation to remove a kidney tumor by removing only part of the kidney leaving healthy tissue.

Creatinine: It is a breakdown product of creatinine phosphate in muscle and is usually produced at a fairly constant rate by the body and excreted by kidneys in urine. The normal serum creatinine range for men is 0.6 mg/dL to 1.3 mg/dL. The normal range for women is 0.5 mg/dL to 1.2 mg/dl (Source: BSMMU biochemistry report, 2018).

Chronic kidney disease: Chronic Kidney Disease (CKD) is a progressive loss in kidney function over a period of months of years (Figure 2).

Endophytic tumor: An Endophytic tumor was defined as less than 40% of the lesion extending off the surface of the kidney.

Exophytic tumor: Tumor that intending to grow outward beyond the surface epithelium from which it originates.

Hypertension: Medical guidelines define hypertension as a blood pressure higher than 130 over 80 millimeters of mercury (mmHg),

according to guidelines issued by the American Heart Association (AHA) in November 2017.

Diabetes: A disease in which the body's ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in when fasting. Less than 7.8 mmol/(140 mg/dl) 2 h after eating. In diabetes patient, blood sugar level in fasting condition ≤ 7.0 mmol/l. Two hours after eating ≥ 11.1 mmol/ (≥ 7.0 mmol/l, 2 hours after eating ≥ 11.1 mmol/l (\geq mg/dl) (Source: BSMMU biochemistry report, 2018).

Results

Distribution of patients by gender show (Table 1), most of the patients in both groups are male. In group A 14 (60.9%) patients are male and 09 (39.1%) patients are female. In group-B, 15 (65.2%) patients are male and 8 (34.8%) patients are female (Table 2), Mean \pm SD, range of age distribution of the patients in group-A is 48.91 ± 8.79 years, (35 to 65) years and in group-B is 5.70 ± 12.23 years, (35 to 74) years (Table 1), Mean \pm SD, BMI in group-A is 20.70 ± 2.36 kg/m² and in group-B is 21.22 ± 6.36 kg/m² (Table 1). There are no statistically significant differences in demographic characteristic (sex,

age) and BMI between two groups ($p=0.760, 0.573, 0.714$ respectively: Table 1).

Pre and post operative symptoms & sign of the patients in both groups shows (Table 2), 18 (78.3%) and 16 (69.6%) of the patients are presented with flank pain at presentation in group-A group-B respectively and rest of the patients have no flank pain. Most of the patients are free from diabetes which are 17 (73.9%) in group-A and 18 (78.3%) in group-B and rest of the patients have no diabetes (Table 2). Hypertension is present in 10 (43.5%) of the patients in both groups and rest of the patients have no hypertensions (Table 2). During post operative period, most of the patients had no post operative fever which are 20 (87.00%) in group-A, 21 (91.3%) in group-B and minorities of the patients have post operative fever in both groups (Table 2). There are no statistically significant differences in pre and post operative clinical symptoms and signs of the patients between two groups ($p=0.502, 0.502, 0.730, 1.000, \text{ and } 1.000$ respectively: Table 2).

Tumor size of kidney of the patients shows (Table 3), mean \pm SD tumor size in group-A 4.28 ± 0.91 , cm, range 2.6 cm to 6.30 cm and

Table 1: Patients characteristics in both groups (n=46).

	Group-A	Group-B	P-Value
	(Nephron-Sparing Surgery) (n=23)	(Radical Nephrectomy) (n=23)	
Sex			
Male	14 (60.9)	15 (65.2)	0.76
Female	9 (39.1)	8 (34.8)	
Age (years)			
(mean \pm SD)	48.91 ± 8.79	5.70 ± 12.23	0.573
Range (years)	35-65	35-74	
BMI (kg/m ²) (mean \pm SD)	20.70 ± 2.36	21.22 ± 6.36	0.714

Chi square test and independent t test was done to measure the level of significance

Table 2: Pre and post operative symptoms & sign of the patients in both groups (n=46).

	Group-A	Group-B	P-Value
	(Nephron-Sparing Surgery) (n=23)	(Radical Nephrectomy) (n=23)	
Pre operative			
Flank pain			
Yes	18 (78.3)	16 (69.6)	0.502
No	5 (21.7)	7 (30.4)	
Hematuria			
Yes	5 (21.7)	7 (30.4)	0.502
No	18 (78.3)	16 (69.6)	
Diabetes			
Yes	6 (26.1)	5 (21.7)	0.73
No	17 (73.9)	18 (78.3)	
Hypertension			
Yes	10 (43.5)	10 (43.5)	1000
No	13 (56.5)	13 (56.5)	
Post Operative			
Fever			
Yes	3 (13.0)	2 (8.69)	1000
No	20 (87.0)	21 (91.30)	

Chi-square test was done to measure the level of significance

Table 3: Distribution of the patients according to tumor characteristics in both groups (n=46).

	Group-A	Group-B	P-Value
	(Nephron-Sparing Surgery) (n=23)	(Radical Nephrectomy) (n=23)	
Tumor size (cm)	4.28 ± 0.91	5.08 ± 0.89	0.004
Ranger (cm)	(2.60-6.30)	(2.90-6.90)	
Tumor location			
Upper pole	9 (39.1)	12 (52.2)	0.563
Lower pole	10 (43.5)	9 (39.1)	
Interpolar	4 (17.4)	2 (8.7)	
Tumor type			
Exophytic	19 (82.6)	5 (51.7)	0.013
Endophytic	4 (17.4)	13 (78.3)	
Hydronephrosis			
Yes	1 (4.3)	2 (8.6)	0.187
No	22 (95.7)	21 (91.3)	
Enhancement			
Yes	23 (100.0)	21 (91.3)	0.489
No	0 (0.0)	2 (8.7)	

Independent' t test and Chi-square test was done to measure the level of significance.

Table 4: Serum creatinine status before and time depended changes after operation (at different follow up) in both groups (n=46).

Serum creatinine	Group-A	Group-B	P-Value
	(Nephron-Sparing Surgery) (n=23)	(Radical Nephrectomy) (n=23)	
Before operation	1.02 ± 0.24	1.07 ± 0.22	0.432
After Operation			
At 1 st POD	1.23 ± 0.28	1.34 ± 0.35	0.236
At 3 rd POD	1.17 ± 0.25	1.32 ± 0.29	0.067
At 7 th POD	1.16 ± 0.19	1.29 ± 0.29	0.087
After 3 months of POD	1.11 ± 0.23	1.35 ± 0.27	0.002
After 6 months of POD	1.14 ± 0.17	1.33 ± 0.21	0.225
After 9 months of POD	1.13 ± 0.16	1.37 ± 0.20	<0.001
After 12 months of POD	1.13 ± 0.16	1.38 ± 0.18	<0.001
Serum creatinine changes (before op vs. after 12 months of POD)	0.11 ± 0.08	0.31 ± 0.04	<0.001
p-value (before op vs. after 12 months of POD)	0.002	0.003	

Independent' t test was done between groups and dependent' t' test was done within group to measure the level of significance

in group-B 5.08 ± 0.89 cm, range 2.9 cm to 6.9 cm. Most of the renal tumors are exophytic 19 (82.6%) and rest of the tumors are endophytic and 18 (78.3%) are endophytic. There are statistically significant differences in tumor size and in tumor type between two groups (p=0.004, 0.013 respectively). In group-A, renal tumors are located in 9 (39.1%) of the patients in the upper pole, 10 (43.5%) in lower pole and 4 (17.4%) in the interpolar (Table 3), In group-B, tumors located in 12 (52.2%) of the patients in the upper pole, 9 (39.1%) in the lower pole and 2 (8.7%) in the interpolar (Table 3). In majority of hepatitis patients had no hydronephrosis in the kidney a diagnosis which are group-A 22 (95.7%) group-B 21 (91.3%) and minorities of the patients have hydronephrosis (Table 3) in group-A all the tumors have contrast enhancement and in group-B 21 (91.3%) had contrast enhancement and 2 (8.7%) had no contrast enhancement (Table 3). There are no statistically significant differences in tumor location, hydronephrosis and in tumor contrast enhancement between two groups (p=0.563, 0.187, 0.489 respectively, Table 3).

During evaluation of patient's serum creatinine status before operation shows (Table 4), mean ± SD serum creatinine in group-A 1.02 ± 0.24 mg/dl and in group-B 1.07 ± 0.22 mg/dl (Table 4) but there is no significant difference preoperatively (p=0.432. After operation, time depended changes of serum creatinine status of the patients at 1st, 3rd and 7th POD in group-A, 1.23 ± 0.28, 1.17 ± 0.25, 1.16 ± 0.19 mg/dl and in group-B, 1.34 ± 0.35, 1.32 ± 0.29, 1.29 ± 0.29 mg/dl respectively (Table 4), but there are no significant differences in serum creatinine status at 1st, 3rd and 7th POD between two groups (p=0.236, 0.067, 0.087 respectively; Table 4). At 3, 6, 9 and 12 months follow up period after operation, time depended mean ± SD serum creatinine status changes in group-A, 1.11 ± 0.23, 1.14 ± 0.17, 1.13 ± 0.16 mg/dl and in group-B, 1.35 ± 0.27, 1.33 ± 0.21, 1.37 ± 0.20, 1.38 ± 0.18 mg/dl respectively (Table 4), but statistically significant differences present in serum creatinine status in 3, 6, 9 and 12 months POD between significant differences present in serum creatinine status in 3, 6, 9 and 12 months POD between significant differences present in serum creatinine status in 3, 6, 9 and 12 months POD between

Table 5: eGFR status before and time depended changes after operation (at different follow up) in both groups (n=46).

eGFR	Group-A	Group-B	P-Value
	(Nephron-Sparing Surgery) (n=23)	(Radical Nephrectomy) (n=23)	
Before operation	7.22 ± 14.48	73.17 ± 17.74	0.671
After operation			
At 1 st POD	64.39 ± 16.05	57.78 ± 11.50	0.116
At 3 rd POD	67.52 ± 15.24	57.43 ± 10.23	0.012
At 7 th POD	67.96 ± 13.66	60.13 ± 13.08	0.053
After 3 months of POD	69.65 ± 14.81	56.61 ± 11.58	0.002
After 6 months of POD	68.39 ± 13.61	55.91 ± 9.49	0.001
After 9 months of POD	68.52 ± 12.52	54.83 ± 10.44	<0.001
After 12 months of POD	68.91 ± 12.86	54.61 ± 10.86	<0.001
Decrease in eGFR (ml/min)	6.31 ± 1.62	18.56 ± 6.88	<0.001
p-value (before op vs. after 12 Months of POD)	<0.001	0.001	<0.001

Independent 't' test was done between groups and dependent 't' test was done within group to measure the level of significance

two groups $p=0.002, 0.002, <0.001, <0.001$ respectively, Table 4). The mean \pm SD serum creatinine status changes from preoperative to 12 months after operation in group-A, 0.11 ± 0.08 mg/dl and in group-B 0.31 ± 0.04 mg/dl which shows statistically significant differences in serum creatinine status between and within the groups ($p<0.001, 0.002, 0.003$ respectively, Table 4).

During evaluation of patient's eGFR status before operation shows (Table 5) mean \pm SD eGFR in group-A, 75.22 ± 14.48 ml/min and in group-B, 73.17 ± 17.74 ml/min (Table 5) but there are no significant differences preoperatively ($p=0.671$). After operation, the time depended changes of eGFR status of the patients at 1st POD in group-A, 64.39 ± 16.05 ml/min and in group-B, 57.78 ± 11.50 ml/min (Table 5) but there is no significant differences in eGFR status at 1st POD between two groups ($p=0.116$, Table 5). At 3rd, 7th POD and 3,6,9,12 months follow up period after operation, time depended mean (\pm SD) eGFR status changes in group-A, $67.52 \pm 15.24, 67.96 \pm 13.66, 69.65 \pm 14.81, 68.39 \pm 13.61, 68.91 \pm 12.86$ ml/min and in group-B, $57.43 \pm 10.23, 60.13 \pm 13.08, 56.61 \pm 11.58, 55.91 \pm 9.49, 54.83 \pm 10.44, 56.61 \pm 10.86$ ml/min respectively; Table 5 but statistically significant differences present in eGFR status in 3rd, 7th POD and 3, 6, 9, 12 months follow up between two groups ('p' value in 3rd, 7th, 3, 6, 9 and 12 months POD= $0.012, 0.053, 0.002, 0.001, <0.001$ respectively; Table 5). The mean \pm SD eGFR status decreased from preoperative to 12 months after operation in group-A 6.31 ± 1.62 ml/min and in group-B 18.56 ± 6.88 ml/min which shows statistically significant differences in eGFR status from preoperative to 12 months follow up between and within the groups ($p<0.001, <0.001, 0.001$ respectively; Table 5).

Discussion

With evolution of imaging modalities (USG, CT/MRI), small and asymptomatic RCC is early diagnosed and the functional and oncological outcome of NSS have increased. Currently, there is controversy regarding the clinical efficacy of NSS and RN in rating localized RCC. According to EAU guideline (2014), nephron sparing surgery is the first treatment option for cT1a tumor (<4 cm) and a viable option for cT1b lesion (>4 cm) when technically feasible [7]. In this prospective study, preoperative and post operative time dependent changes of renal function up to 12 months after NSS (Group-A) and RN (Group-B) are assessed by measuring eGFR using MDRD formula as renal function tends to be overestimated by using serum



Figure 1: CT finding of right renal mass (RCC) in coronal and axial view (Source: case no-24, 2017).

creatinine which is affected by several factors affecting creatinine generation. In this study, the risk factors for the development of new onset of CKD (eGFR<60 ml/min) after operation are observed but univariate or multivariate logistic regression analysis to predict association with renal function is not done. With regard to patient baseline characteristics (age, sex, BMI) in the current study, no significant differences ($p=0.760, 0.573, 0.714$ respectively) are noted that can affect renal function. An interesting finding is that the age ranges in group-A, (35 to 65) years and in group-B, (35 to 74) years but classically renal tumors occur in sixth and seventh decades of Life. The early occurrence of tumors in the current study perhaps due to easier access or exposure to carcinogen (smoking, industrial chemicals) and more rapid diagnostic and therapeutic methods available currently; additionally, many patients are diagnosed and therapeutic methods available currently; additionally, many patients are diagnosed incidentally during medical evaluation for other symptoms [8]. Although compensatory hypertrophy occurs in all age groups after nephrectomy due to increased renal plasma flow and more pronounced in <30 years of age, effective renal plasma flow is known to decrease with patient age resulting in decreased compensatory hypertrophy with increased age and progressive deterioration of renal function. Most of the patients in both groups are male (NSS=60.9%, RN=65.2%) that indicates renal cell carcinoma is more prevalence in male and similar result (NSS=67.5%, RN=66%) was also reported by Scosyrev et al. [9]. The male predominance in our country may be




Figure 2: CTP finding of right renal ass (RCC) - coronal and axial view (Source case no-17, 2017).

due to presence of increasers' factors n male (cigarette smoking, job profession in various chemical industries and exposure to toxins). Male patients had a significantly greater increase in effective renal plasma flow as well creatinine clearance than female patients at 1 week ($p < 0.005$) and at 1 year ($p < 0.0001$) after nephrectomy due to more compensatory hypertrophy than female [10]. In case of BMI, obese patients ($>30 \text{ kg/m}^2$) are excluded from this study and the result is slightly differ (average $21 \text{ vs. } 23 \text{ kg/m}^2$) from study noted by Miyamoto et al. [6], because majority of study population are low income group and most of them are note overweight. In pre and post operative symptoms & sign (flank pain, hematuria, diabetes, hypertension, post operative fever) of the patients in both groups have no significant differences ($p = 0.502, 0.502, 0.730, 1.00, 1.00$ respectively) and do not influence renal function, Different results were observed, in which flank pain 48% in Ochsner clinic and 50% in UCLA hospital that were lower than present study (in group-A 78.3%, group-B 69.6% respectively) because they are more diagnosed incidentally and may get immediate management for pain. Though hematuria is the late presentation but within this study. Hematuria is higher in group-B than group-A (21.7% vs.30.4%) because most of the tumors are larger and endophytic in group-B which may involve the PCS and may causes hematuria 35% in St. Luke's Hospital, 40% n Ochsner clinic and in Mayo clinic 32%. Minorities of the patients in this study have hypertension and diabetes that are well controlled preoperatively, intro operatively and postoperatively up to follow up period by measuring regular blood pressure with getting anti hypertensive drugs, measuring blood sugar level with giving short acting insulin, oral hypoglycemic agents and alive is given to control hypertension was reported 44% in NSS, 60.8% in RN by Liss et al. [11], compared to 43.5% in both groups of current study due to heir sedentary life styles and consumption of lipid rich food. Several conflicting studies examined the long-term effects of renal donation on the contralesional kidney. Anderson et al. [10] noted that renal donors might be at slightly increased risk for the development of hypertension secondary to chronic hyperfiltration after unilateral nephrectomy. Miller et al. [12] reported that 31% of the patients develop hypertension after donor nephrectomy but has no significant impact on renal function

($p < 0.05$). In baseline tumor characteristics, eman tumor size differs according to type of surgery in which larger tumor in group-B (5.8 cm) than group-A (4.28 cm) which influence the renal function in the present study ($p = 0.004$) because larger tumor reduce more functional renal parenchyma. Leivovich et al. [7] reported that 4 cm or smaller RCC showed better quality of life and less renal impairment for NSS than for RN. Comparable result is observed from the study by Simon et al. [13], which reported that mean tumors size in NSS was 3.63 cm and in RN 5.54 cm and there was statistically significant difference ($p < 0.001$). Different results were also observed in several studies due to large sample size and early incidental diagnosis of tumors in which mean & SD tumor type (central vs. peripheral) had no impact no renal function (serum creatinine 1.43 mg/dl in both groups) although NSS in technically more difficult in centrally located lesions leading to longer ischemia times and increased incidence of collecting system injuries. Other tumor characteristics (tumor location, contrast enhancement, hydronephrosis) have been examined for their association with outcomes in patients with RCC but there are no statistically significant differences ($p < 0.05$). In group-A, lower polar tumors are more (43.5%) and in group-B, upper polar tumors are more (52.2%). There is minimal difference in the current study from another study by Patel et al. [14], which showed that tumors were located 34% in upper pole, 34% in the lower pole and 9% in the mid portion, In general, it is accepted that renal tumor enhancement of >15 Hounsfield Units (HU) in CT is suggestive of a malignancy [15]. The CT enhances have shown a significant association with histological subtypes of renal cell cancer in which heterogeneous enhancement pattern is seen in clear-cell RCC compared with chromophobe and papillary RCCs [16]. In this study, all the tumors in group-A and 91.3% tumors in group-B have contrast enhancement and rest of the tumors have USG features of RCC but statistically no significant difference is present ($p = 0.489$). In majority of the patients had no hydronephrosis in the kidney during diagnoses which are 95.7% in group-A and 91.3% in group-B. No study was reported relating to contrast enhancement, hydronephrosis and renal function. In preoperative period, mean serum creatinine status in lower in group-A than in group-B (1.02 vs. 1.07 mg/dl; Table 4) and have no significant difference ($p = 0.4320$). Different mean serum creatinine results (NSS=0.83 mg/dl, RN=1.7 mg/dl; $p < 0.001$) in the study by krebs et al. [17], were seen due to large sample size. The lower serum creatinine level in the current study may be due to more functioning renal parenchyma and small tumor size in affected kidney of group-A than group-B.

After operation, time-dependent changes of serum creatinine status of the patients at 1st, 3rd and 7th POD are less pronounced in group-A than group-B (Figure 1) and have no significant differences in both groups ($p > 0.05$) but at 3, 6, 9 and 12 months, the changes remain stable up to 12 months in group-A but increases gradually in group-B (Figure 1) and have no significant differences in both groups ($p > 0.002$). Similar result was documented by Miyamoto et al. [6], in post operative serum creatinine level between two groups (NSS=96 mg/dl, RN=1.24 mg/dl; $p < 0.001$). From preoperative to 12 Months after operation, mean creatinine status changes is less in group-A (0.11 mg/dl) than in group-B (0.31 iomg/dl) and have statistically significant differences in between and within the groups ($p = 0.002, 0.003$ respectively). Comparable result found by Clark et al. [18], in a Prospective study in which creatinine clearance dropped more RN (0.56 ml/min, 31.6%) than NSS (0.09 ml/min, 6.1%) and $p < 0.001$. Hakim and Ringden et al. [19] documented that the removal

of one kidney from a patient with two normally functioning kidneys results in functional adaptation and compensatory hypertrophy of the remaining kidney. Creatinine clearance increases to 70% to 75% of the preoperative creatinine clearance within several weeks post operatively. Several studies have followed patients for more than 10 years after donor nephrectomy and found that creatinine clearance remained stable. In preoperative period, mean eGFR is more in group-A (75.22 ml/min) than in group-B (73.17 ml/min) due to small tumor size and more functioning renal parenchyma and have no significant difference ($p > 0.671$.) Similar eGFR results were observed in the studies (71.4 vs. 71.3 ml/min, $p > 0.05$) by Miyamoto et al. [6] and (80.2 vs. 78.2 vs. 78.2 ml/min; $P > 0.05$) by Pignot. The time depended changes mean eGFR status at 1st POD is not significant ($P = 0.116$) but at 3rd, 7th POD and 3, 6, 9, 12 months, it becomes significant in both groups ($P < 0.001$) because of more residual functioning renal parenchyma present after NSS. Comparable result are noted by Mariusdottir et al. [4], in which significant differences was observed postoperatively and after 60 months (56 vs. 44 ml/min, $p < 0.001$; 59 vs. 45 ml/min; $p < 0.001$). The mean eGFR decreased more significantly in group-B (18.56 ml/min) than group-A (6.31 ml/min) from preoperative to 12 months after operation and have significant difference ($p < 0.001$; Table 5). The current results differ from the study by Miyamoto et al. [6], in which eGFR decrease by 9.27 ml/min in NSS and 25.1 ml/min ($p < 0.0002$) in RN due to large tumor size is NSS and large sample size (152 patients). The time-dependent changes of eGFR after RN show plateau from initially and then gradually declining from the first postoperative day to the 12 postoperative months. In case of NSS, a lowest eGFR is observed in postoperative day 1 and gradually recovered to near preoperative level for 12 months (Anderson et al. [10] reported that compensatory hypertrophy was completed 1 week after donor nephrectomy and Tanaka et al. [20], reported 2 to 4 weeks after RN. Krebs et al. [17] reported that eGFR in NSS patients were higher than RN in postoperatively. The compensatory hypertrophy after donor nephrectomy has previously been believed to be beneficial but compensatory hyperfiltration due to arterial vasodilatation with increased flow and eventually proteinuria, azotemia and hypertension but does not lead to long term decrease in renal function [10]. At the end of discussion, the present study suggested that although compensatory hypertrophy occurs in the early postoperative day in RN than NS, renal functional outcome is more stable in NSS than RN due to functioning residual renal parenchyma.

Conclusion

Time dependent changes of estimated Glomerular Filtration Rate (eGFR) after nephron-sparing surgery is better than Radical Nephrectomy (RN) for Renal Cell Carcinoma (RCC) in 12 months follow up period. NSS has minimal impact on post operative renal function measured by eGFR whereas RN is associated with significantly greater renal function decline. NSS is therefore the better procedure for preservation of renal function.

Limitations of the Study

- Small sample size
- Lack of longer follow up (only 12 months)
- Surgery is performed by multiples surgeons.
- Associated risk factors are not evaluated by logistic regression analysis.
- Patients with renal failure (eGFR < 30 ml/min), obese

patients and pregnant women are not included in the present study.

Recommendations

Observing time depended changes of eGFR of the present study. It can be said that nephron sparing surgery has preserved renal function more than radical nephrectomy. With this view in mind following recommendation are put for consideration of future researchers as well as relevant authority.

- Regular practice of nephron sparing surgery in patients with localized RCC in our country.
- Large sample size should be taken for further study.
- Longer follow up should be given.
- Intervention should be done by single surgeon.
- Meta analysis for further evaluation of renal function.

References

1. Graham SD, Keane TE, Glenn JF. Glenn's urologic surgery. Philadelphia: Lippincott Williams & Wilkins; 2010.
2. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology: Expert consult premium edition: Enhanced online features and print, 4-volume set. USA: Elsevier Health Sciences; 2011. p. 1414-20.
3. Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW, Thuroff JW. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. *J Urol*. 2006;175(6):2027-31.
4. Mariusdottir El, Jonsson E, Marteinson VT, Sigurdsson MI, Gudbjarnsson T. Kidney function following partial or radical nephrectomy for renal cell carcinoma a population based study. *Scand J Urol*. 2013;47(6):476-82.
5. Ertekin E, Amasyals AS, Erol B, Acikagooglu S, Kucukdurmaz F, Nayman A, et al. Role of contrast enhancement and corrected attenuation values of renal tumors in predicting Renal Cell Carcinoma (RCC) subtypes: Protocol for triphasic multi-slice Computed Tomography (CT) procedure. *Pol J Radiol*. 2017;82:384-91.
6. Miyamoto K, Inoue S, Kajiwara M, Teishima J, Matsubara A. Comparison of renal function after partial nephrectomy and radical nephrectomy for renal cell carcinoma. *Urol Int*. 2012;89(2):227-32.
7. Leibovich BC, Blute ML, Chevillie JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm result in outcome similar to radical nephrectomy. *J Urol*. 2004;171(3):1066-70.
8. Joudi FN, Allareddy V, Kane CJ, Konety BR. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. *J Urol*. 2007;177(5):1709-14.
9. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: Results from EORTC randomized trial 30904. *Eur Urol*. 2014;65(2):372-7.
10. Anderson RG, Buseschen AJ, Lloyd LK, Dubovsky EV, Burns JR. Short-term and long-term changes in renal function after donor nephrectomy. *J Urol*. 1991;145(1):11-3.
11. Liss MA, DeConde R, Caovan D, Hofler J, Gabe M, Plazzi KL, et al. Parenchymal volumetric assessment as a predictive tool to determine renal function benefit of nephron-sparing surgery compared with radical nephrectomy. *J Endourol*. 2016;30(1):114-21.
12. Miller JJ, Suthanthiran M, Riggio RR, Williams JJ, Riehel RA, Vaughan ED, et al. Impact of renal donation. Long-term clinical and biochemical follow-up of living donors in a single center. *Am J Med*. 1985;79(2):201-8.
13. Antonelli A, Cozzoli A, Nicolai M, Zani D, Zanotelli T, Perucchini L, et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of

- intracapsular renal cell carcinoma up to 7 cm. *Eur Urogl.* 2008;53(4):803-9.
14. Patel NP, Lavengood RW. Renal cell carcinoma: Natural history and results of treatment. *J Urol.* 1978;119(6):722-6.
15. Atri M, Tabatabaeifar L, Jang HJ, Finelli A, Moshonov H, Jewett M. Accuracy of contrast enhanced US for differentiating benign from malignant solid small renal masses. *Radiology.* 2015;276(3):489-92.
16. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: A systematic review and meta-analysis. *J Urol.* 2012;188(1):51-7.
17. Krebs RK, Andreoni C, Ortiz V. Impact of radical and partial nephrectomy on renal function in patients with renal cancer. *Urol Int.* 2014;92(4):449-54.
18. Clark AT, Breau RH, Morash C, Fergusson D, Doucette S, Cagiannos L. Preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance. *Eur Urol.* 2008;54(1):143-9.
19. Hakim RM, Goldzzer RC, Renner BM. Hypertension and proteinuria: Long-term sequel of uninephrectomy in humans. *Kidney Int.* 1984;25(6):930-6.
20. Tanaka N, Fujimoto K, Tani M, Yoshii M, Yoshida K, Hirao Y, et al. Predictions of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. *Urology.* 2004;64(5):904-8.